Truncation, randomization, and selection: generation of a reduced length c-Jun antagonist that retains high interaction stability

• Published in: The Journal of biological chemistry Vol. 286; no. 34; pp. 29470 - 29479
• Main Authors: Crooks, Richard O, Rao, Tara, Mason, Jody M
• Format: Journal Article
• Language: English
• Published: United States American Society for Biochemistry and Molecular Biology 26.08.2011
• Subjects: Humans; Leucine Zippers; Peptides - chemistry; Peptides - metabolism; Protein Binding; Protein Structure and Folding; Protein Structure, Tertiary; Proto-Oncogene Proteins c-fos - antagonists & inhibitors; Proto-Oncogene Proteins c-fos - chemistry; Proto-Oncogene Proteins c-fos - metabolism; Proto-Oncogene Proteins c-jun - antagonists & inhibitors; Proto-Oncogene Proteins c-jun - chemistry; Proto-Oncogene Proteins c-jun - metabolism; Structure-Activity Relationship
• DOI: 10.1074/jbc.M111.221267
• ISSN: 1083-351X; 0021-9258

The DNA binding activity of the transcriptional regulator activator protein-1 shows considerable promise as a target in cancer therapy. A number of different strategies have been employed to inhibit the function of this protein with promise having been demonstrated both in vitro and in vivo. Peptide-based therapeutics have received renewed interest in the last few years, and a number of 37-amino acid peptides capable of binding to the coiled coil dimerization domain of Jun and Fos have been derived. Here, we demonstrate how truncation and semi-rational library design, followed by protein-fragment complementation, can be used to produce a leucine zipper binding peptide by iterative means. To this end, we have implemented this strategy on the FosW peptide to produce 4hFosW. This peptide is truncated by four residues with comparably favorable binding properties and demonstrates the possibility to design progressively shorter peptides to serve as leucine zipper antagonists while retaining many of the key features of the parent peptide. Whether or not the necessity for low molecular weight antagonists is required from the perspective of druggability and efficacy is subject to debate. However, antagonists of reduced length are worthy of perusal from the point of view of synthetic cost as well as identifying the smallest functional unit that is required for binding.